Beijing Shengyong Pharmaceutical Co., Ltd.

Primary study objective: To investigate the relative bioavailability of a single oral tablet of the test preparation epalrestat tablets (specification: 50 mg/tablet, produced by Jiangsu Yongan Pharmaceutical Co., Ltd., provided by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd.) and the reference preparation epalrestat tablets [trade name: KINEDAK, specification: 50 mg/tablet, produced by Alfresa Pharma Corporation, provided by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd.] in healthy adult Chinese subjects in the fasting state, to analyze the pharmacokinetic parameters of the two preparations, and to evaluate the bioequivalence of the two preparations. Secondary study objective: To evaluate the safety of a single oral tablet of the test preparation and the reference preparation epalrestat tablets (specification: 50 mg/tablet) in healthy adult Chinese subjects in the fasting state.

Main study objectives: To investigate the relative bioavailability of the single-dose oral (fasting/postprandial) test preparation metformin empagliflozin tablets (I) (specification: 500mg/5mg, produced by Jiangsu Yongan Pharmaceutical Co., Ltd. commissioned by Beijing Shengyong Pharmaceutical Co., Ltd.) and the reference preparation metformin empagliflozin tablets (I) (SYNJARDY?, specification: 500mg/5mg, Boehringer Ingelheim Pharmaceuticals Inc. licensed) in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. Secondary study objectives: To evaluate the safety of the single oral fasting and postprandial test preparations and reference preparations in healthy Chinese adult subjects.

Studying the effects of diet